INTRODUCTION {#s05}
============

Worldwide, every year, there are nearly 800,000 patients diagnosed with liver cancer; it is the sixth most common malignancy and the third most lethal malignancy.^[@B1],[@B2]^ Almost three quarters of new patients live in areas with low- and medium-income areas.^[@B1]^ Liver cancer can occur in association with chronic hepatitis B virus (HBV) infection in the presence or absence of cirrhosis.^[@B3]^ Other risk factors include hepatic cirrhosis of any etiology, excessive consumption of alcohol, exposure to aflatoxins, certain inherited diseases, and metabolic disorders such as obesity, diabetes, and nonalcoholic fatty liver disease.^[@B4]^

Guatemala is a country of more than 16 million inhabitants, according to the Guatemalan National Institute of Statistics, and has a low- to middle-income economy. In Guatemala, noncommunicable diseases account for approximately half of total deaths, with cancer accounting for approximately 12% of all deaths.^[@B5]^ Guatemala has the highest incidence and mortality rates of all types of malignancies in Central and South America, including liver cancer, with a unique 1:1 distribution in men and women.^[@B6]-[@B8]^

Compared with other areas of the world where the highest incidence rates of liver cancer are in regions with the highest prevalence of predisposing conditions such as chronic HBV and hepatitis C virus (HCV) infections, according to previous studies, Guatemala has a low endemicity (less than 2%) of carriers of HBV.^[@B1],[@B9],[@B10]^ It is also estimated that there are approximately 145,000 persons infected with HCV, but approximately 80% are unaware that they carry the virus.^[@B11],[@B12]^

Since 2013, the Health Ministry has required that general practitioners and specialists report new cancer cases every 3 months.^[@B13]^ In addition, the National Commission for the Prevention of Noncommunicable Diseases and Cancer was created by the Health Ministry with the aim to develop policies and actions to decrease the incidence, prevalence, mortality, and disability associated with noncommunicable diseases, counting on technical and financial support from the Pan American Organization of Health and the Institute of Nutrition of Central America and Panama. The program has developed a guideline for the prevention and management of cancer in the first and second levels of attention in the country; in this guideline, it is mentioned that α-fetoprotein and ultrasound should be used for the diagnosis of liver cancer. Guatemala lacks in most areas the resources for these diagnostic tests; thus, screening the populations at risk for developing liver cancer is not possible.^[@B14]^

Despite the high mortality rate in Guatemala as a result of liver cancer, little is known about the risk factors in this population or regional distribution of the disease, which makes it difficult to create a program for prevention and screening for people at risk. In this context, we analyzed the national data available, not just regarding liver cancer, but also regarding the risk factors related to liver cancer, such as alcoholism, cirrhosis, and HBV infection. We also discuss the HBV immunization program.

METHODS {#s07}
=======

We performed a secondary analysis from 2012 to 2016 using official national sources of information. For both mortality and morbidity of liver cancer, we included the International Classification of Diseases, 10th Revision, codes for liver cancer (C22, C22.1 to C22.9) and liver carcinoma in situ (D01.5). HBV, cirrhosis, and alcoholism data were obtained from the Work Memory from 2012 to 2015, along with data for immunizations; 2016 data were unavailable at the time of this study. All the data were obtained from the Guatemalan Health Ministry, available online in the Health Information System.^[@B15]^ For the calculations of mortality and incidence, we used population data from the National Institute of Statistics. For age-specific mortality and incidence rates, we divided the populations in quinquennial age groups. All graphs and tables were generated using spreadsheets in Microsoft Office Excel 2013 (Microsoft, Redmond, WA), and a map of the country was created using Microsoft Paint on the basis of percentages of deaths as a result of liver cancer per department in the year 2016.

RESULTS {#s08}
=======

Mortality of Liver Cancer {#s09}
-------------------------

In Guatemala, cancer is a leading cause of death, accounting for 7.46% of all deaths in 2016. Over a period of 5 years, there was a decrease in cancer-related deaths from 23 to 21 per 100,000 inhabitants. Although deaths as a result of all cancers decreased in the general population, the liver cancer mortality rate showed a tendency to increase and accounted for approximately 20% of all deaths related to malignant tumors ([Table 1](#T1){ref-type="table"} and [Fig 1](#f1){ref-type="fig"}).

###### 

Mortality for Liver Cancer and All Cancers (crude rate per 100,000 inhabitants) in Guatemala From 2012 to 2016
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![Liver cancer mortality (crude rate) per 100,000 inhabitants in Guatemala from 2012 to 2016.](JGO.18.00179f1){#f1}

On average, liver cancer rates have a female-to-male ratio of 1:1 for all age groups, and the age group with the highest percentage of reported deaths (41.24%) was the population older than age 65 years ([Table 2](#T2){ref-type="table"} and [Fig 2](#f2){ref-type="fig"}). Approximately three quarters of deaths were reported in people older than age 54 years; however, although liver cancer rates seem to be decreasing from previous years for this population, an increase of 50% in liver cancer--related death was seen in the population between 30 and 44 years old in 2016 compared with 2012 ([Table 2](#T2){ref-type="table"} and [Fig 2](#f2){ref-type="fig"}). Most liver cancer--related deaths have occurred in the departments of San Marcos, Alta Verapaz, and Huehuetenango, contributing to more than 30% of all deaths as a result of this malignancy in 2016 ([Table 3](#T3){ref-type="table"} and [Fig 3](#f3){ref-type="fig"}).

###### 

Age-Specific Liver Cancer Mortality (crude rate per 100,000 inhabitants) in Guatemala From 2012 to 2016
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![Age-specific liver cancer mortality (crude rate) per 100,000 inhabitants in Guatemala from 2012 to 2016.](JGO.18.00179f2){#f2}

###### 

Distribution of Liver Cancer Deaths in Guatemala From 2012 to 2016
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![Distribution of liver cancer deaths in Guatemala in 2016.](JGO.18.00179f3){#f3}

Incidence of Liver Cancer {#s10}
-------------------------

Unlike for cervical cancer, liver malignancies lack a strategy for early detection and screening of the at-risk population; however, we still analyzed the available information. The incidence of cancer has remained steady among the population, with 11 cancers per 100,000 inhabitants ([Table 4](#T4){ref-type="table"} and [Fig 4](#f4){ref-type="fig"}). The incidence of liver cancer has increased approximately 33% from 2012, and liver cancer only represents approximately 3% of all malignancies detected, with six of 10 patients being age 55 years or older ([Table 5](#T5){ref-type="table"} and [Fig 5](#f5){ref-type="fig"}).

###### 

Incidence Rates of Liver Cancer and All Cancers per 100,000 Inhabitants in Guatemala From 2012 to 2016
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![Liver cancer incidence rates per 100,000 inhabitants in Guatemala from 2012 to 2016.](JGO.18.00179f4){#f4}

###### 

Age-Specific Liver Cancer Incidence Rate per 100,000 Inhabitants in Guatemala From 2012 to 2016
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![Age-specific liver cancer incidence rates per 100,000 inhabitants in Guatemala from 2012 to 2016.](JGO.18.00179f5){#f5}

Incidence and Mortality of Risk Factors for Liver Cancer {#s11}
--------------------------------------------------------

In Guatemala, since 2012, there has been a decrease in the incidence of major risk factors for the development of liver cancer ([Table 6](#T6){ref-type="table"} and [Fig 6](#f6){ref-type="fig"}). Currently, in contrast with HCV, there is epidemiologic surveillance of HBV infections, and the incidence of HBV has been reduced by half in Guatemala ([Table 6](#T6){ref-type="table"} and [Fig 6](#f6){ref-type="fig"}).

###### 

Incidence and Mortality Rate (per 100,000 inhabitants) of Liver Cancer Risk Factors in Guatemala From 2012 to 2015
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![Incidence (per 100,000 inhabitants) of risk factors for liver cancer in Guatemala from 2012 to 2015. HBV, hepatitis B virus. \*Cirrhosis mortality rate.](JGO.18.00179f6){#f6}

Since 2013, the National Health System has offered free immunization against HBV along with bacillus Calmette-Guérin at birth, with a coverage rate of 29% among new births. In contrast, the pentavalent vaccine covers more than three quarters of children younger than 1 year old with a complete schedule, but less than 5% of children have received a booster dose by the age of 1 to 6 years .

Liver cirrhosis incidence and mortality rates experienced a dramatic decrease in 2014, but its incidence has increased more than 200% over a period of 4 years (2012 to 2016). In contrast, alcoholism has shown a reduction in incidence among the Guatemalan population ([Fig 6](#f6){ref-type="fig"}).

DISCUSSION {#s12}
==========

By 2030, Guatemala will have more than 20 million inhabitants, and as the population ages and the nativity rates decline in Central America, it is expected that the incidence of all cancers will increase by approximately 73%.^[@B4]^ The data presented here demonstrate that despite a reduction in cancer-related deaths among the population, the incidence is steady, which will lead to an overwhelming burden for the health system. In addition, although the incidence of liver cancer seems low compared with that of other malignancies, its high mortality indicates that few patients are diagnosed early in the course of the disease. The reasons for this could include the lack of access to health services, low knowledge in the population about the disease, and perceptions about the diagnosis of cancer.

According to 2015 data from The World Bank, 59.1% of Guatemalans live in poverty. The diagnosis of a malignancy could lead to additional impoverishment as a result of its effects on the daily economic situation, often related to the loss of income and health care expenses. To reduce the burden of this malignancy in Guatemala, it is important to create a screening program for the population at risk, including patients with cirrhosis, alcoholism, and HBV or HCV. It is also crucial to investigate whether there are other risk factors associated with liver cancer in Guatemalans, such as aflatoxin exposure and genetic variations. This might help us understand why the disease is increasing among young adults and would provide valuable information that could allow for the creation of measures to prevent the disease or identify patients at an earlier stage.

However, an excellent screening program is only appropriate if there are effective treatment measures that are accessible to patients. Although chemotherapy and radiotherapy are available to the public, only four public or government-supported hospitals offer these treatments in Guatemala, and all of them are located in Guatemala City. Approximately 80% of the population lives outside of the capital of Guatemala City; thus, for many patients, treatment is out of reach or requires traveling long distances.^[@B16]-[@B18]^ Considering the fact that most patients are diagnosed with late-stage disease, many patients need palliative care, but currently, there are no policies that guarantee access to palliative care to patients, causing unnecessary pain for the patients and their families.^[@B19]-[@B21]^

Liver cancer incidence is low compared with that of other malignancies in the country, but its high mortality rate indicates that few patients are diagnosed before developing late-stage disease. Reducing the burden of liver cancer in Guatemala requires not only making screening more available for the population at risk, but also identifying other risk factors to enact prevention measures to decrease the risk of the disease.

AUTHOR CONTRIBUTIONS {#s13}
====================

**Conception and design:** All authors

**Administrative support:** Angel Velarde

**Provision of study material or patients:** María F. Toledo-Ponce

**Collection and assembly of data:** Alba J. Kihn-Alarcón

**Data analysis and interpretation:** Alba J. Kihn-Alarcón, Angel Velarde

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

AUTHORS\' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST {#s14}
========================================================

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO\'s conflict of interest policy, please refer to <http://www.asco.org/rwc> or [ascopubs.org/jco/site/ifc](https://ascopubs.org/jco/site/ifc).

No potential conflicts of interest were reported.
